Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 9, 2008, Pages 3539-3544

  Li, Shaowei ^a   Takeuchi, Fumiko ^a   Wang, Ji An ^a   Fan, Qingyuan ^a   Komurasaki, Toshi ^b   Billings, Eric M ^c   Pacheco Rodriguez, Gustavo ^c   Moss, Joel ^c   Darling, Thomas N ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Angiofibromas; Paracrine; Periungual fibromas; TSC1; TSC2

Indexed keywords

EPIREGULIN; HAMARTIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; TUBERIN; EPIDERMAL GROWTH FACTOR; MESSENGER RNA; PROTEIN KINASE; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM CELL; FIBROBLAST; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HAMARTOMA; HEMANGIOFIBROMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MESENCHYME CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN DISEASE; TUBEROUS SCLEROSIS COMPLEX; EPITHELIUM; GENE EXPRESSION PROFILING; GENETICS; MESODERM; METABOLISM; PARACRINE SIGNALING; PATHOLOGY; TUBEROUS SCLEROSIS;

MAMMALIA;

CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; EPITHELIUM; GENE EXPRESSION PROFILING; HAMARTOMA; HUMANS; MESODERM; PARACRINE COMMUNICATION; PROTEIN KINASES; RNA, MESSENGER; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 42149191944     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0712397105     Document Type: Article

References (43)

1. Darling TN (2006) Hitting the mark in hamartoma syndromes. Adv Dermatol 22:181-200.
2. Kwiatkowski DJ, Manning BD (2005) Tuberous sclerosis: A GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14:R251-R258.
3. Astrinidis A, Henske EP (2005) Oncogene 24:7475-7481.
4. Jozwiak S, Schwartz RA, Janniger CK, Michalowicz R, Chmielik J (1998) Skin lesions in children with tuberous sclerosis complex: Their prevalence, natural course, and diagnostic significance. Int J Dermatol 37:911-917.
5. Sweeney SM (2004) Pediatric dermatologic surgery: A surgical approach to the cutaneous features of tuberous sclerosis complex. Adv Dermatol 20:117-135.
6. Benjamin DR (1996) Cellular composition of the angiofibromas in tuberous sclerosis. Pediatr Pathol Lab Med 16:893-899.
7. Nickel WR, Reed WB (1962) Tuberous sclerosis: Special reference to the microscopic alterations in the cutaneous hamartomas. Arch Dermatol 85:209-226.
8. Reed RJ, Ackerman AB (1973) Pathology of the adventitial dermis: Anatomic observations and biologic speculations. Hum Pathol 4:207-217.
9. Sanchez NP, Wick MR, Perry HO (1981) Adenoma sebaceum of Pringle: A clinicopathologic review, with a discussion of related pathologic entities. J Cutan Pathol 8:395-403.
10. Weston J, Apfelberg DB, Maser MR, Lash H, White D (1985) Carbon dioxide laserbrasion for treatment of adenoma sebaceum in tuberous sclerosis. Ann Plast Surg 15:132-137.
11. Pasyk KA, Argenta LC (1988) Argon laser surgery of skin lesions in tuberous sclerosis. Ann Plast Surg 20:426-433.
12. Niida Y, et al. (2001) Survey of somatic mutations in tuberous sclerosis complex (TSC) hamartomas suggests different genetic mechanisms for pathogenesis of TSC lesions. Am J Hum Genet 69:493-503.
13. Henske EP, et al. (1997) Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 151:1639-1647.
14. Fuchs E (2007) Scratching the surface of skin development. Nature 445:834-842.
15. Werner S, Krieg T, Smola H (2007) Keratinocyte-fibroblast interactions in wound healing. J Invest Dermatol 127:998-1008.
16. van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM (2003) The tumor microenvironment: A critical determinant of neoplastic evolution. Eur J Cell Biol 82:539-548.
17. Li S, et al. (2005) MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. J Exp Med 202:617-624.
18. Karbowniczek M, Yu J, Henske EP (2003) Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and nonneoplastic vascular structures. Am J Pathol 162:491-500.
19. Chan JA, et al. (2004) Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: Biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 63:1236-1242.
20. +/- mice on a Blm-deficient background. Cancer Res 65:10179-10182.
21. Meikle L, et al. (2005) A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes. Hum Mol Genet 14:429-435.
22. Fackler I, et al. (2003) Loss of expression of tuberin and hamartin in tuberous sclerosis complex-associated but not in sporadic angiofibromas. J Cutan Pathol 30:174-177.
23. Nguyen-Vu PA, et al. (2001) Loss of tuberin, the tuberous-sclerosis-complex-2 gene product, is associated with angiogenesis. J Cutan Pathol 28:470-475.
24. Toyoda H, Komurasaki T, Ikeda Y, Yoshimoto M, Morimoto S (1995) Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development. FEBS Lett 377:403-407.
25. Lindvall C, et al. (2003) Molecular characterization of human telomerase reverse transcriptase-immortalized human fibroblasts by gene expression profiling: Activation of the epiregulin gene. Cancer Res 63:1743-1747.
26. Yamamoto T, et al. (2004) Expression of betacellulin, heparin-binding epidermal growth factor, and epiregulin in human malignant fibrous histiocytoma. Anticancer Res 24:2007-2010.
27. Torring N, Hansen FD, Sorensen BS, Orntoft TF, Nexo E (2005) Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition. Prostate 64:1-8.
28. Zhu Z, et al. (2000) Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 273:1019-1024.
29. Toyoda H, et al. (1995) Epiregulin, a novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 270:7495-7500.
30. Shirakata Y, et al. (2000) Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J Biol Chem 275:5748-5753.
31. Takahashi M, et al. (2003) Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells. Circulation 108:2524-2529.
32. Draper BK, Komurasaki T, Davidson MK, Nanney LB (2003) Topical epiregulin enhances repair of murine excisional wounds. Wound Repair Regen 11:188-197.
33. Shirakata Y, et al. (2007) Epiregulin, a member of the EGF family, is overexpressed in psoriatic epidermis. J Dermatol Sci 45:69-72.
34. Varley C, et al. (2005) Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. Exp Cell Res 306:216-229.
35. Inatomi O, et al. (2006) Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts. Int J Mol Med 18:497-503.
36. Patel RD, Kim DJ, Peters JM, Perdew GH (2006) The aryl hydrocarbon receptor directly regulates expression of the potent mitogen epiregulin. Toxicol Sci 89:75-82.
37. Toyoda H, Komurasaki T, Uchida D, Morimoto S (1997) Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J 326:69-75.
38. Zhou M, Li XM, Lavker RM (2006) Transcriptional profiling of enriched populations of stem cells versus transient amplifying cells: A comparison of limbal and corneal epithelial basal cells. J Biol Chem 281:19600-19609.
39. Kim HS, et al. (2007) Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development. J Biol Chem 282:16278-16287.
40. Roach ES, Gomez MR, Northrup H (1998) Tuberous sclerosis complex consensus conference: Revised clinical diagnostic criteria. J Child Neurol 13:624-628.
41. Kato M, et al. (1992) Expression of glial fibrillary acidic protein (GFAP) by cultured angiofibroma stroma cells from patients with tuberous sclerosis. Neuropathol Appl Neurobiol 18:559-565.
42. Pfutzner W, Hengge UR, Joari MA, Foster RA, Vogel JC (1999) Selection of keratinocytes transduced with the multidrug resistance gene in an in vitro skin model presents a strategy for enhancing gene expression in vivo. Hum Gene Ther 10:2811-2821.
43. Pacheco-Rodriguez G, et al. (2007) TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res 67:10573-10581.